MCM
IART icon

Mazama Capital Management’s Integra LifeSciences IART Stock Holding History

Mazama Capital Management’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-1,341
Closed -$20K – 266
2013
Q2 		$20K Buy
+1,341
New +$19.7K 0.01% 181

Other funds holding IART

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
VNIM
Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return
CI
Cambiar Investors Denver, Colorado $2.16B AUM 16.24% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Mazama Capital Management's IART Position: Q3 2013 in Review

Mazama Capital Management sold out of Integra LifeSciences (IART) in Q3 2013, closing a stake of 1,341 shares — an estimated $20K sold.

Mazama Capital Management first reported a position in IART in Q2 2013 and held it in 1 quarter. The position peaked at $20K in Q2 2013. 131 funds tracked by Wall St. Rank hold IART as of Q3 2013.

  • Mazama Capital Management reported no remaining Integra LifeSciences position as of Q3 2013 after selling out during the quarter.
  • Mazama Capital Management sold 1,341 Integra LifeSciences shares in Q3 2013, an estimated $20K.
  • Mazama Capital Management first reported a position in Integra LifeSciences in Q2 2013 and held it in 1 quarter.
  • Mazama Capital Management's Integra LifeSciences position peaked at $20K in Q2 2013.
  • 131 funds tracked by Wall St. Rank held Integra LifeSciences as of Q3 2013.

Based on Mazama Capital Management's 13F filing for Q3 2013, filed 8 Nov 2013.